share_log

The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma

Benzinga ·  Nov 10, 2023 07:03
The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment